Applications of nanotechnology for immunology

Nature Reviews Immunology

Volumn 13, Issue 8, 2013, Pages 592-605

  Smith, Douglas M ^a   Simon, Jakub K ^b   Baker, James R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NanoBio Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CAMPTOTHECIN; CYCLOSPORIN; DEXAMETHASONE; FULLERENE DERIVATIVE; INACTIVATED VACCINE; INFLUENZA VACCINE; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; MELAN A; MIFAMURTIDE; NANOMATERIAL; NANOPARTICLE; RAPAMYCIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ESCHERICHIA COLI; GENETIC RECOMBINATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGY; LYMPHOCYTE PROLIFERATION; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VACCINATION;

EID: 84880877024     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3488     Document Type: Review

References (149)

1. Watson, J. D. & Crick, F. H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171, 737-738 (1953).
2. Mandelkern, M., Elias, J. G., Eden, D. & Crothers, D. M. The dimensions of DNA in solution. J. Mol. Biol. 152, 153-161 (1981).
3. Jennings, G. T. & Bachmann, M. F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu. Rev. Pharmacol. Toxicol. 49, 303-326 (2009).
4. Buonaguro, L., Tagliamonte, M., Tornesello, M. L. & Buonaguro, F. M. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines 10, 1569-1583 (2011).
5. Goldinger, S. M. et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. Eur. J. Immunol. 42, 3049-3061 (2012). This Phase IIa clinical trial shows both the advantages and the potential limitations of using an improved MelQbG10 virus-like nanoparticle (30 nm) vaccine displaying MART1 on the surface together with integrated and exogenous TLR agonists for the enhanced generation of TH1 cell responses and effector or memory CD8+ T cell activation in late stage cancer patients.
6. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008). This paper shows that polystyrene nanoparticles of a defined size (20-200 nm), or VLPs (30 nm) biodistribute rapidly to the draining lymph nodes to be taken up by lymph node resident DCs, whereas larger nanoparticles (500-2,000 nm) are acquired by DCs at the site of injection to be subsequently transported to the lymphatic tissues. This establishes nanoscale size as a crucial parameter for the mechanism of biodistribution and delivery and for vaccine applications.
7. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotech. 25, 1159-1164 (2007). This paper uses polyethylene glycol-stabilized polypropylene sulfide nanoparticles in the absence of specific targeting ligands to show efficient passive distribution of nanoparticles to the draining lymph nodes on the basis of size using differently sized particles of identical composition. (Pubitemid 47538111)
8. Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A. & Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control Release 112, 26-34 (2006).
9. Fifis, T. et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004). (Pubitemid 39142021)
10. Cruz, L. J. et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control Release 144, 118-126 (2010). This study shows a crucial contribution of nanoscale size to the uptake of targeted nanoparticles by DCs.
11. Paliard, X. et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16, 273-282 (2000). (Pubitemid 30111963)
12. Schirmbeck, R., Bohm, W. & Reimann, J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39, 111-119 (1996).
13. Buonaguro, L. et al. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res. 54, 189-201 (2002). (Pubitemid 34327684)
14. Kaba, S. A. et al. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS ONE 7, e48304 (2012). This paper shows SAPNs, consisting of multiple 125 amino acid-long polypeptide subunits engineered to express repetitively displayed B cell and T cell epitopes derived from an antigen of the causative agent of human malaria, activate long-lasting (>1 year) and high-affinity protective cellular and humoral immune responses in a mouse model, which is an important proof of principle for progression to clinical trials using this novel vaccine platform.
15. Douglas, R. G. Jr. The heritage of hepatitis B vaccine. JAMA 276, 1796-1798 (1996).
16. Hilleman, M. R., McAleer, W. J., Buynak, E. B. & McLean, A. A. The preparation and safety of hepatitis B vaccine. J. Infect. 7 (Suppl. 1), 3-8 (1983). (Pubitemid 13042284)
17. Buonaguro, L., Petrizzo, A., Tornesello, M. L. & Buonaguro, F. M. Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18, 23-34 (2011).
18. No, J. H., Kim, M. K., Jeon, Y. T., Kim, Y. B. & Song, Y. S. Human papillomavirus vaccine: widening the scope for cancer prevention. Mol. Carcinog. 50, 244-253 (2011).
19. Grun, J. L. & Maurer, P. H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell. Immunol. 121, 134-145 (1989). (Pubitemid 19160191)
20. Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P. & Cambier, J. C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808-1810 (2004). (Pubitemid 38787898)
21. Bomford, R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 39, 426-434 (1980).
22. Brewer, J. M. (How) do aluminium adjuvants work? Immunol. Lett. 102, 10-15 (2006). (Pubitemid 41606034)
23. Gupta, R. K., Rost, B. E., Relyveld, E. & Siber, G. R. Vaccine Design: The Subunit and Vaccine Approach 229-248 (Plenum, 1995).
24. Wijburg, O. L. et al. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. J. Immunol. 28, 479-487 (1998). (Pubitemid 28101723)
25. Naim, J. O., van Oss, C. J., Wu, W., Giese, R. F. & Nickerson, P. A. Mechanisms of adjuvancy: I-metal oxides as adjuvants. Vaccine 15, 1183-1193 (1997). (Pubitemid 27372099)
26. Zanetti, A. R., Van Damme, P. & Shouval, D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26, 6266-6273 (2008).
27. Martinez-Sernandez, V. & Figueiras, A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J. Neurol. 20 Oct 2012 [epub ahead of print].
28. Boato, F. et al. Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew. Chem. Int. Ed. Engl. 46, 9015-9018 (2007). This paper uses a lipopeptide monomer incorporating a coiled-coil self-assembly motif in which the lipid tails form a central core to stabilize the particle and enable the multivalent display of antigens in a nanometre-scale (~20 nm) synthetic VLP vaccine platform. (Pubitemid 350232757)
29. Mascola, J. R. & Montefiori, D. C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28, 413-444 (2010).
30. Wang, B. Z. et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J. Virol. 81, 10869-10878 (2007).
31. Riedel, T. et al. Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. Chembiochem 12, 2829-2836 (2011). This report shows that synthetic VLPs can be engineered by structural vaccinology to stimulate immune responses targeted against narrowly-defined and critically exposed regions of an antigen, as for the induction of HIV-1-neutralizing antibodies against gp120.
32. Ghasparian, A. et al. Engineered synthetic virus-like particles and their use in vaccine delivery. Chembiochem 12, 100-109 (2011).
33. McBurney, S. P. & Ross, T. M. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 27, 4337-4349 (2009).
34. Scherer, E. M., Leaman, D. P., Zwick, M. B., McMichael, A. J. & Burton, D. R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl Acad. Sci. USA 107, 1529-1534 (2010).
35. Julien, J. P. et al. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J. Virol. 84, 4136-4147 (2010).
36. Sanou, M. P., De Groot, A. S., Murphey-Corb, M., Levy, J. A. & Yamamoto, J. K. HIV-1 vaccine trials: evolving concepts and designs. Open AIDS J. 6, 274-288 (2012).
37. Look, M., Bandyopadhyay, A., Blum, J. S. & Fahmy, T. M. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Deliv. Rev. 62, 378-393 (2010).
38. Mundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P. & Aminabhavi, T. M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control Release 125, 193-209 (2008). This article provides an overview of the concept and the importance of ordered and repetitive structural arrays expressed by VLPs and other nanoparticles for the optimal induction of B cell responses using the example of gp23, which is the major capsid protein of bacteriophage T4.
39. Bharali, D. J. et al. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine 4, 311-317 (2008).
40. Chou, H. Y. et al. Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells. J. Immunol. 185, 5468-5475 (2010).
41. Raman, S., Machaidze, G., Lustig, A., Aebi, U. & Burkhard, P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2, 95-102 (2006). (Pubitemid 43956613)
42. Baschong, W., Hasler, L., Haner, M., Kistler, J. & Aebi, U. Repetitive versus monomeric antigen presentation: direct visualization of antibody affinity and specificity. J. Struct. Biol. 143, 258-262 (2003). (Pubitemid 37297864)
43. Schroeder, U. et al. Peptide nanoparticles serve as a powerful platform for the immunogenic display of poorly antigenic actin determinants. J. Mol. Biol. 386, 1368-1381 (2009).
44. Pimentel, T. A. et al. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 73, 53-61 (2009).
45. Babapoor, S. et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res. Treat. http://dx.doi.org/10.1155/2011/126794 (2012).
46. Kaba, S. A. et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183, 7268-7277 (2009).
47. Wahome, N. et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem. Biol. Drug Des. 80, 349-357 (2012).
48. O'Hagan, D. T., Tsai, T. & Reed, S. in Influenza Vaccines for the Future 2nd edn (eds Rappuoli, R. & Del Giudice, G.) 327-357 (Springer, 2011).
49. Vogel, F. R., Caillet, C., Kusters, I. C. & Haensler, J. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines 8, 483-492 (2009).
50. Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812-1823 (2011).
51. Seubert, A., Monaci, E., Pizza, M., O'Hagan, D. T. & Wack, A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180, 5402-5412 (2008).
52. Wack, A. et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26, 552-561 (2008).
53. Bernstein, D. I. et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197, 667-675 (2008). (Pubitemid 351364465)
54. Schultze, V. et al. Safety of MF59 adjuvant. Vaccine 26, 3209-3222 (2008).
55. Barchfeld, G. L. et al. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 17, 695-704 (1999). (Pubitemid 29074723)
56. Boyce, T. G. et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19, 217-226 (2000). (Pubitemid 30621515)
57. Stanberry, L. R. et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 30, 307-316 (2012).
58. Makidon, P. E. et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 3, e2954 (2008).
59. Makidon, P. E. et al. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur. J. Immunol. 42, 2073-2086 (2012).
60. Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nature Rev. Immunol. 9, 353-363 (2009). This article provides an overview of immunogenic cell death as a concept used to describe signals produced by dying cells or expressed on the cell surface that lead to the activation of innate and adaptive immune responses rather than to the induction of unresponsiveness or tolerance. This is an important consideration for particular types of nanoparticles that are known to induce apoptosis or necrosis as this could potentially be related to vaccine immunogenicity.
61. Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Med. 13, 54-61 (2007). (Pubitemid 46067386)
62. Hamouda, T. et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J. Infect. Dis. 180, 1939-1949 (1999).
63. Hamouda, T. & Baker, J. R. Jr. Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. J. Appl. Microbiol. 89, 397-403 (2000).
64. Hamouda, T. et al. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol. Res. 156, 1-7 (2001). (Pubitemid 32430537)
65. Donovan, B. W. et al. Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions. Antivir. Chem. Chemother. 11, 41-49 (2000). (Pubitemid 30083894)
66. Bielinska, A. U. et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin. Vaccine Immunol. 15, 348-358 (2008). (Pubitemid 352025538)
67. Lindell, D. M. et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE 6, e21823 (2011).
68. Myc, A. et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 21, 3801-3814 (2003). (Pubitemid 37338208)
69. Makidon, P. E. et al. Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med. Microbiol. Immunol. 199, 81-92 (2010).
70. Bielinska, A. U. et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun. 75, 4020-4029 (2007). (Pubitemid 47206301)
71. Bielinska, A. U. et al. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 24, 271-281 (2008). (Pubitemid 351282102)
72. Durrer, P. et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21, 4328-4334 (2003). (Pubitemid 37130275)
73. Kamath, A. T. et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE 4, e5771 (2009).
74. Christensen, D., Korsholm, K. S., Andersen, P. & Agger, E. M. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 10, 513-521 (2011).
75. Henriksen-Lacey, M. et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J. Control Release 145, 102-108 (2010). This study evaluates the biodistribution of separately radiolabelled lipids and antigens to show the gradual release or depot effect to be a crucial delivery mechanism, in combination with innate activation and monocyte infiltration, for cationic liposome-based vaccines after intramuscular administration to mice.
76. Henriksen-Lacey, M. et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 8, 153-161 (2011).
77. Brunel, F., Darbouret, A. & Ronco, J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 17, 2192-2203 (1999). (Pubitemid 29197288)
78. Werninghaus, K. et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ-Syk- Card9-dependent innate immune activation. J. Exp. Med. 206, 89-97 (2009).
79. Bal, S. M., Hortensius, S., Ding, Z., Jiskoot, W. & Bouwstra, J. A. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 29, 1045-1052 (2011).
80. Zhou, S., Kawakami, S., Yamashita, F. & Hashida, M. Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett. 287, 75-81 (2010).
81. Zaks, K. et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176, 7335-7345 (2006). (Pubitemid 43849034)
82. Whitmore, M. M., Li, S., Falo, L. Jr & Huang, L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50, 503-514 (2001). (Pubitemid 34028283)
83. Zolnik, B. S., Gonzalez-Fernandez, A., Sadrieh, N. & Dobrovolskaia, M. A. Nanoparticles and the immune system. Endocrinology 151, 458-465 (2010).
84. Nielsen, G. D., Roursgaard, M., Jensen, K. A., Poulsen, S. S. & Larsen, S. T. In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin. Pharmacol. Toxicol. 103, 197-208 (2008).
85. Mitchell, L. A. et al. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol. Sci. 100, 203-214 (2007). (Pubitemid 47617817)
86. Bosi, S., Da Ros, T., Spalluto, G. & Prato, M. Fullerene derivatives: an attractive tool for biological applications. Eur. J. Med. Chem. 38, 913-923 (2003). (Pubitemid 37455402)
87. Ryan, J. J. et al. Fullerene nanomaterials inhibit the allergic response. J. Immunol. 179, 665-672 (2007). (Pubitemid 46986585)
88. Tkach, A. V. et al. Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS Nano 5, 5755-5762 (2011).
89. Mitchell, L. A., Lauer, F. T., Burchiel, S. W. & McDonald, J. D. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nature Nanotechnol. 4, 451-456 (2009). This work explores the mechanisms by which multi-walled carbon nanotubules have a direct effect on immunomodulation.
90. Liu, R. et al. Research on the bioactivities of C60-dexamethasone. J. Nanosci. Nanotechnol. 9, 3171-3176 (2009).
91. Konduru, N. V. et al. Phosphatidylserine targets single-walled carbon nanotubes to professional phagocytes in vitro and in vivo. PLoS ONE 4, e4398 (2009).
92. Muller, R. H. & Keck, C. M. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113, 151-170 (2004). (Pubitemid 39237077)
93. Shen, L. J. & Wu, F. L. Nanomedicines in renal transplant rejection - focus on sirolimus. Int. J. Nanomed. 2, 25-32 (2007).
94. Kaminskas, L. M., McLeod, V. M., Porter, C. J. & Boyd, B. J. Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. Mol. Pharm. 9, 355-373 (2012).
95. Kannan, S. et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci. Transl. Med. 4, 130ra146 (2012). This article shows that the beneficial effect of the anti-inflammatory agent NAC is enhanced by polyamidoamine dendrimers and suggests that the enhanced effect is due to the enhanced delivery of the anti-inflammatory agent.
96. Shaunak, S. et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nature Biotech. 22, 977-984 (2004). (Pubitemid 39014474)
97. Barata, T. S., Teo, I., Brocchini, S., Zloh, M. & Shaunak, S. Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput. Biol. 7, e1002095 (2011).
98. Teo, I. et al. Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers. EMBO Mol. Med. 4, 866-881 (2012).
99. Shukla, N. M. et al. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS ONE 7, e43612 (2012).
100. Higaki, M., Ishihara, T., Izumo, N., Takatsu, M. & Mizushima, Y. Treatment of experimental arthritis with poly(d, l-lactic/glycolic acid) nanoparticles encapsulating β-methasone sodium phosphate. Ann. Rheum. Dis. 64, 1132-1136 (2005). (Pubitemid 41113345)
101. Buyuktimkin, B. et al. Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Mol. Pharm. 9, 979-985 (2012).
102. Park, J. et al. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm. 8, 143-152 (2011).
103. Slutter, B. et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28, 6282-6291 (2010).
104. Baca-Estrada, M. E., Foldvari, M. & Snider, M. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J. Interferon Cytokine Res. 19, 455-462 (1999). (Pubitemid 29269935)
105. Keijzer, C. et al. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 6, e26684 (2011). This work shows that specific properties of a nanoparticle, including charge and route of administration, have a differential effect on the immune response.
106. Landesman-Milo, D. & Peer, D. Altering the immune response with lipid-based nanoparticles. J. Control Release 161, 600-608 (2012).
107. Musacchio, T. & Torchilin, V. P. Recent developments in lipid-based pharmaceutical nanocarriers. Front. Biosci. 16, 1388-1412 (2011).
108. Gaca, J. G. et al. Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. J. Surg. Res. 112, 19-25 (2003). (Pubitemid 36836175)
109. Richards, P. J., Williams, B. D. & Williams, A. S. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology 40, 978-987 (2001).
110. Epstein, H. et al. Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J. 10, 505-515 (2008).
111. Zheng, X. et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 113, 2646-2654 (2009).
112. Koo, O. M., Rubinstein, I. & Onyuksel, H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm. Res. 28, 776-787 (2011).
113. Khaja, F. A., Koo, O. M. & Onyuksel, H. Nanomedicines for inflammatory diseases. Methods Enzymol. 508, 355-375 (2012).
114. Wang, S. H., Fan, Y., Makidon, P. E., Cao, Z. & Baker, J. R. Induction of immune tolerance in mice with a novel mucosal nanoemulsion adjuvant and self-antigen. Nanomedicine 7, 867-876 (2012). This study shows that nanoemulsion-enhanced uptake of self antigens results in a decreased humoral immune response, upregulation of FOXP3 and TGFβ expression, and increased TReg cell activity.
115. Bielinska, A. U. et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit. Rev. Immunol. 30, 189-199 (2010).
116. McAleer, J. P. & Vella, A. T. Educating CD4 T cells with vaccine adjuvants: lessons from LPSsaccharide. Trends Immunol. 31, 429-435 (2010).
117. Wiersinga, W. J. Current insights in sepsis: from pathogenesis to new treatment targets. Curr. Opin. Crit. Care 17, 480-486 (2011).
118. Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475-487 (2009).
119. Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632 (2007). (Pubitemid 46982038)
120. Dubensky, T. W. Jr & Reed, S. G. Adjuvants for cancer vaccines. Semin. Immunol. 22, 155-161 (2010).
121. Yosef, N. et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 496, 461-468 (2013). In this paper, the silicon composition, needle-like shape and dimensions of vertical-oriented nanowires are used in a new way to penetrate the T cell membrane without cellular toxicity to introduce siRNA into the cytosol as a means to evaluate the network of genes regulating TH17 cell differentiation.
122. US National Nanotechnology Initiative. What is nanotechnology? Nano.gov [online], http://www.nano.gov/nanotech-101/what/definition (2012).
123. US Food and Drug Administration. Considering whether an FDA-regulated product involves the application of nanotechnology: guidance for industry. FDA [online], http://www.FDA.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm (2011).
124. European Medicines Agency. Nanotechnology. [online], http://www.ema. europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content- 000345.jsp&mid=WC000340b000301ac005800baed000349&jsenabled=true (2012).
125. Tao, Y. & Zhang, L. Characterization of polysaccharide-protein complexes by size-exclusion chromatography combined with three detectors. Carbohydr. Res. 343, 2251-2257 (2008).
126. Erickson, H. P. Size and shape of protein molecules at the nanometer level determined by sedimentation, gel filtration, and electron microscopy. Biol. Proced. Online 11, 32-51 (2009).
127. Choe, J., Kelker, M. S. & Wilson, I. A. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309, 581-585 (2005). (Pubitemid 41033635)
128. Klein, J. S. et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl Acad. Sci. USA 106, 7385-7390 (2009).
129. Arechaga, I. et al. Structural characterization of the TCR complex by electron microscopy. Int. Immunol. 22, 897-903 (2010).
130. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Rev. Immunol. 10, 787-796 (2012).
131. Alexopoulos, C. J., Mims, C. W. & M., B. Introductory Mycology (John Wiley and Sons, 1996).
132. Yaeger, R. G. in Medical microbiology 4th edn Ch. 77 (ed. Baron, S.) (Univ. of Texas Medical Branch at Galveston, 1996).
133. Lipscomb, M. F. & Masten, B. J. Dendritic cells: immune regulators in health and disease. Physiol. Rev. 82, 97-130 (2002). (Pubitemid 34654216)
134. Krombach, F. et al. Cell size of alveolar macrophages: an interspecies comparison. Environ. Health Perspect. 105 (Suppl. 5), 1261-1263 (1997).
135. DeFranco, A. L. Structure and function of the B cell antigen receptor. Annu. Rev. Cell Biol. 9, 377-410 (1993).
136. Weiss, A. Structure and function of the T cell antigen receptor. J. Clin. Invest. 86, 1015-1022 (1990). (Pubitemid 20370403)
137. Zucker-Franklin, D. Atlas of Blood Cells: Function and Pathology (Lea & Febiger,1981).
138. Weller, P. F. Eosinophils: structure and functions. Curr. Opin. Immunol. 6, 85-90 (1994). (Pubitemid 24050710)
139. Hamdy, S. et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26, 5046-5057 (2008).
140. Zhang, Z. et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32, 3666-3678 (2011).
141. Uenaka, A. et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 7, 9 (2007).
142. Kitano, S. et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin. Cancer Res. 12, 7397-7405 (2006). (Pubitemid 46095414)
143. Nochi, T. et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nature Mater. 9, 572-578 (2010).
144. Gu, X. G. et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res. 58, 3385-3390 (1998).
145. Ikuta, Y. et al. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99, 3717-3724 (2002). (Pubitemid 34534543)
146. Vangala, A. et al. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control Release 119, 102-110 (2007). (Pubitemid 46561543)
147. Frazer, I. H. et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23, 172-181 (2004). (Pubitemid 39505086)
148. Maraskovsky, E. et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin. Cancer Res. 10, 2879-2890 (2004). (Pubitemid 38509168)
149. Mitchell, J. E. et al. The presumptive phosphatidylserine receptor is dispensable for innate anti-inflammatory recognition and clearance of apoptotic cells. J. Biol. Chem. 281, 5718-5725 (2006). (Pubitemid 43847670)